News|Videos|November 17, 2026

Obexelimab Cuts Glucocorticoid Toxicity in IgG4-RD: Matthew Baker, MD

Fact checked by: Victoria Johnson

Matthew Baker, MD, MS, discusses INDIGO data showing obexelimab lowered cumulative glucocorticoid toxicity in IgG4-related disease at ACR 2026.

Obexelimab significantly lowered cumulative glucocorticoid toxicity versus placebo over 52 weeks in patients with IgG4-related disease (IgG4-RD), according to a Glucocorticoid Toxicity Index (GTI) analysis of the phase 3 INDIGO trial.1 Matthew C. Baker, MD, MS, associate professor of medicine and associate division chief of immunology and rheumatology at Stanford University, discussed the findings in an interview.

Baker presented the data at ACR Convergence 2026, held November 6-11 in Orlando, Florida. INDIGO randomized patients with active IgG4-RD to obexelimab 250 mg or placebo subcutaneously once weekly for 52 weeks after glucocorticoid induction, with a standardized taper to discontinuation by week 8 and rescue glucocorticoids permitted for flares.1 Least-squares mean cumulative rescue dose through week 52 was 329.5 mg with obexelimab versus 929.8 mg with placebo (difference, −600.3 mg; P = .004).2

"So there was a difference of 600 milligrams. So that sounds like a lot, but again, we don't know exactly what that translates into clinically, and so that's where the GTI comes in," Baker said.

The analysis used 8 GTI domains, excluding bone mineral density, for which the minimal clinically important difference is 15 points.1 At week 52, the GTI Cumulative Worsening Score was 28.2 with obexelimab versus 39.6 with placebo (difference, −11.4; 95% CI, −21.1 to −1.7; P = .021), following a numerical, nonsignificant difference at week 24. Fewer patients receiving obexelimab worsened by at least 20 points (42.2% vs 61.2%; P = .013) or at least 30 points (28.9% vs 49.4%; P = .009).

Most domains favored obexelimab, led by infection (−5.3), glucocorticoid myopathy (−2.0), and neuropsychiatric toxicity (−1.9), although Baker noted the trial was not powered for domain-level comparisons.1 Hyperlipidemia scores rose slightly with obexelimab (+1.0), skin toxicity was similar, and the Aggregate Improvement Score did not differ significantly (difference, −4.6; P = .47). These congress data have not been peer reviewed.

Baker said the B-cell–depleting inebilizumab will play a major role in IgG4-RD care, while a nondepleting B-cell inhibitor could be theoretically safer and preferred by some patients, although head-to-head and longer-term data are lacking. He said he hopes both agents, if obexelimab is approved, are used early to minimize glucocorticoid exposure, and he called for prospective GTI use in more rheumatology trials. Open-label extension data from INDIGO, also presented at ACR, showed durable flare control with continued obexelimab.

Relevant disclosures for Baker include AbbVie, Amgen, argenx, Eli Lilly, Gilead, Sanofi, and Zenas BioPharma.

References
  1. Baker M, Perugino C, Della-Torre E, et al. Obexelimab reduced glucocorticoid-associated toxicity in patients with IgG4-related disease: results from the phase 3 randomized, placebo-controlled INDIGO trial. Abstract 1882. Presented at: ACR Convergence 2026; November 6-11, 2026; Orlando, FL. https://acrabstracts.org/abstract/obexelimab-reduced-glucocorticoid-associated-toxicity-in-patients-with-igg4-related-disease-results-from-the-phase-3-randomized-placebo-controlled-indigo-trial/
  2. Della-Torre E, Baker MC, Zhang W, et al. Obexelimab for the treatment of IgG4-related disease. N Engl J Med. Published online June 2, 2026. doi:10.1056/NEJMoa2601337

Related to this article